Previous 10 | Next 10 |
Intra-Cellular Therapies (ITCI +74% on positive topline results from its Phase 3 clinical trial. More news on: Astrotech Corporation, Vaxart, Inc., Chembio Diagnostics, Inc., Stocks on the move, , Read more ...
Are These Good Penny Stocks To Buy Right Now? If you’re looking for good penny stocks to buy right now, what are you looking for? I’m sure momentum is one thing and maybe, news is another. But what about chart patterns? Is technical analysis part of your strategy? Many trade...
OCALA, FL / ACCESSWIRE / September 8, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), today announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at ...
The following slide deck was published by AIM ImmunoTech Inc. in conjunction with this Read more ...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
3 Penny Stocks To Buy Now Or Avoid Entire; You Decide Penny stocks are an interesting asset class. Some tend to have no rhyme or reason to their movement. While others you would think to have broken out after big news remain dormant. A lot of this comes down to who knows about these companie...
AIM ImmunoTech ( AIM +12.3% ) has identified an effective in vitro model for testing Ampligen, a dsRNA TLR3 agonist, against COVID-19. More news on: AIM ImmunoTech Inc., Healthcare stocks news, Stocks on the move, Read more ...
OCALA, FL / ACCESSWIRE / August 27, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) is pleased to announce that it has identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results show t...
OCALA, FL / ACCESSWIRE / August 25, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it will be presenting at The LD 500 Investor conference being held virtually on September 1-4, 2020. Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to present on Tu...
LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new subgroup analysis from Phase 2b trials with...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...